29-09-2019 | Breast cancer | Video
ESMO 2019: MONARCH 2 update – OS gain with abemaciclib plus fulvestrant
George Sledge Jr reports overall survival data for the MONARCH 2 trial investigating the addition of the CDK4/6 inhibitor abemaciclib to fulvestrant in women with HR-positive, HER2-negative metastatic breast cancer (2:49).
Funding for independent interviews at ESMO 2019 was provided in part by F.Hoffmann-La Roche Ltd, Basel, Switzerland.